GLP-1s not a ‘lifestyle product’ – The Star
GLP-1s not a ‘lifestyle product’ The StarCalls to poison centers skyrocket amid rise in use of GLP-1 drugs, experts…
Ten-million-person study links semaglutide to lower COVID-19 mortality
After accounting for major health differences between semaglutide users and non-users, researchers identified a striking mortality association that…
Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits
A large US health-record study suggests newer GLP-1 drugs may reduce alcohol-related acute-care visits, but the findings remain…
GLP-1 receptor agonists may increase hair loss risk
Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased…
Popular diabetes drugs do not alter the risk of developing a blinding eye condition
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – a type of…
Nearly one in 10 Britons use or want weight-loss medication
A nationally representative survey estimates that millions of adults in Great Britain have already used GLP-1-based weight-loss medicines…
GLP-1RAs linked to lower risk of amputation in diabetes with PAD
The largest meta-analysis to date suggests GLP-1RAs may reduce major limb complications in people with type 2 diabetes…
GLP-1 exposure in pregnancy does not clearly raise major birth defect risk
Large-scale evidence offers cautious reassurance after inadvertent GLP-1 exposure in pregnancy, but unresolved risks and low-certainty data mean…
Simple blood test could identify the most effective obesity drug
A simple fasting blood test measuring two key incretin hormones could help match patients with severe obesity to…
GLP-1 drugs combined with surgery yield superior weight loss results
People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery…
A new tool that predicts obesity-related disease risk beyond BMI
A data-driven tool built from nearly 200,000 individuals reveals who is most likely to develop serious obesity-related diseases,…
GLP-1 drugs promise wider health benefits, but experts urge caution on use
As GLP-1 receptor agonists move beyond blood sugar and weight loss, a new review shows why clinicians must…